Tennessee GLP-1 & Weight Loss Med Spa Compliance (2026)

Weight-loss medicine has become the economic engine of the modern med spa. GLP-1 receptor agonists — semaglutide and tirzepatide — drive the highest-intent search traffic, the strongest recurring revenue, and, increasingly, the most regulatory attention. In Tennessee, that attention has a specific legal home: unlike most states, Tennessee regulates medical spas through a dedicated medical spa registration rule, and a GLP-1 program does not sit outside it.

This is the Tennessee-specific companion to our national GLP-1 med spa compliance guide. The federal picture — the end of the compounding shortage exemptions, the branded-product landscape, the good-faith-exam expectation — applies in Tennessee too, and we won't repeat all of it here. What this guide does is layer Tennessee's structure on top: the medical spa registration statute, who may prescribe and administer under the Board of Medical Examiners and Board of Nursing, telehealth prescribing under state law, sourcing constraints, and the monitoring and documentation a program must be able to produce on demand.

If you operate — or plan to operate — a GLP-1 weight-loss program in Tennessee, this guide tells you exactly where the lines are.

Why Tennessee's Med Spa Statute Shapes Every GLP-1 Program

Most states leave med spas to be governed indirectly, through general scope-of-practice and corporate-practice rules. Tennessee is different: it has a rule written specifically for medical spas, and that rule is the frame around everything a weight-loss program does.

The Registration Rule

Under the Tennessee Board of Medical Examiners' medical spa rule (Tenn. Comp. R. & Regs. 0880-02-.24), a medical spa must register with the state and operate under a licensed physician — an MD or DO with an active Tennessee license and an active Tennessee medical practice — who attests to accepting responsibility for the facility's cosmetic medical services. The registered physician's name and certification are disclosed in the practice's signage and advertising. This is not a formality: it is the legal hook that ties every clinical act in the building back to a named, accountable physician.

Why Weight Loss Is Squarely Covered

A GLP-1 program is the practice of medicine by any definition — it involves diagnosing a patient's suitability for a prescription drug, prescribing that drug, and injecting it. There is no reading of the medical spa rule under which weight-loss injections escape medical oversight. The registered supervising physician (or medical director) is responsible for the weight-loss program's protocols, its delegation chain, and its adherence to the standard of care. Operators who imagine that a "wellness" or "nutrition" label lets a GLP-1 line operate outside the registered medical structure are mistaken — and exposed.

How This Compares to Neighboring Rules

The same registration-and-oversight logic governs Tennessee's injectable market. If you have read our guide to who can inject Botox in Tennessee, the structure here will feel familiar: a registered physician on top, delegation flowing down to qualified providers, and bright lines around who may diagnose and prescribe versus who may administer. GLP-1 simply adds a prescribing-and-sourcing layer on top of that injectable-scope foundation.

Who Can Prescribe Semaglutide and Tirzepatide in Tennessee

Prescribing authority is the first question every GLP-1 operator has to answer, and Tennessee draws it clearly around three license types.

Physicians (MD/DO)

A Tennessee-licensed physician has full authority to evaluate a patient, perform the good-faith exam, and prescribe semaglutide or tirzepatide. In most med spa structures the physician is also the registered supervising physician or medical director and sits at the top of the delegation chain — approving the program's protocols and overseeing the mid-level prescribers who do the day-to-day volume.

APRNs Under a Collaborative Practice Agreement

Tennessee does not grant nurse practitioners full practice authority. An advanced practice registered nurse (APRN) who diagnoses, develops a plan of care, or prescribes must hold a certificate of fitness from the Board of Nursing and must practice under a written collaborative practice agreement with a supervising physician. Within that framework, an APRN can perform the good-faith exam and prescribe GLP-1s. The collaborating physician must have experience in the relevant area of practice, and the agreement — a dated, signed written protocol — must be maintained at the practice site.

Physician Assistants Under a Supervisory Agreement

A physician assistant may prescribe GLP-1 medication under a written supervisory agreement approved through the Board of Medical Examiners' process, with a supervising physician who accepts oversight responsibility. As with APRNs, the PA can perform the good-faith exam and prescribe within that agreement. GLP-1 receptor agonists are not controlled substances, so the additional DEA and Tennessee controlled-substance registration steps that apply to controlled drugs are not triggered by semaglutide or tirzepatide themselves — though a prescriber still needs them for any controlled medication they handle.

Who Cannot Prescribe

A registered nurse, a licensed practical nurse, a medical assistant, and an esthetician cannot prescribe GLP-1 medication under any circumstance. Neither can a non-clinician owner. A structure in which a business owner or an RN "runs the weight-loss program" and a physician is paid a flat fee to rubber-stamp prescriptions inverts the delegation chain the medical spa rule requires — and the Board looks at substance, not labels.

The Good-Faith Exam Before Any GLP-1 Prescription

The good-faith exam is the linchpin of weight-loss compliance in Tennessee and the most common point of failure in high-volume programs.

What Tennessee Requires

Before prescribing or dispensing any drug, a Tennessee prescriber must perform an appropriate history and physical examination, make a diagnosis consistent with good medical care, formulate and discuss a therapeutic plan (including the risks and benefits of the treatment options), and ensure availability for appropriate follow-up. The Board of Medical Examiners has not published a single rigid checklist defining "appropriate" for every situation — which means the standard of care, not a shortcut, governs. For a weight-loss patient, that means a real clinical evaluation, not a form.

Who Can Perform It

The good-faith exam must be performed by a physician, APRN, or physician assistant acting within scope. It cannot be performed or delegated to a registered nurse, an LPN, or a medical assistant. This is the rule that trips up scaled operations: the prescriber must actually evaluate the patient and document a diagnosis and plan before any nurse administers an injection.

What to Document

For a defensible GLP-1 good-faith exam, chart the following:

• Verified anthropometrics — measured height, weight, and BMI, not a self-reported figure when the patient can be weighed
• Medical and weight history — prior weight-loss attempts, current medications, allergies, relevant surgical history
• Comorbidities — type 2 diabetes, prediabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease — these establish medical necessity
• Contraindication screen — personal or family history of medullary thyroid carcinoma (MTC), MEN-2, pancreatitis, gastroparesis, pregnancy or pregnancy planning, severe renal or hepatic impairment
• Informed consent — risks, benefits, common GI adverse events, serious risks (pancreatitis, gallbladder disease, the MTC boxed warning), and off-label use where applicable
• Treatment plan — starting dose, titration schedule, monitoring, follow-up cadence, and discontinuation criteria

The full national documentation set lives in the complete GLP-1 guide; Tennessee's distinction is that the exam itself — not merely the paperwork — is treated as a non-delegable medical act tied to the registered physician.

Who Can Administer GLP-1 Injections in Tennessee

Registered nurses are the workhorse of most injection programs, but Tennessee puts firm walls around what they can and cannot decide.

What an RN Can Do

A Tennessee RN can administer a GLP-1 injection that a qualified prescriber has already ordered, perform follow-up weight and vitals checks, provide patient education, and document the encounter. They do this under physician delegation and a valid order tied to the prescriber's prior good-faith exam. Administration is squarely within RN scope; it is the injecting, not the deciding, that the RN is authorized to do.

What an RN Cannot Do

An RN cannot perform the good-faith exam, diagnose the patient, select who is appropriate for treatment, or make the prescribing decision. A "standing order" that lets a nurse approve weight-loss intakes without a prescriber's individualized exam is not valid delegation — it is the unlicensed practice of medicine, and it exposes both the nurse and the delegating physician. The delegation authorizes administration, never the decision to prescribe.

Medical Assistants and Estheticians

Medical assistants and estheticians cannot administer GLP-1 injections at all. The same scope logic that governs neurotoxin and filler injection in Tennessee applies here: injecting a prescription drug is a delegated medical or nursing act, not a cosmetic service an unlicensed staff member may perform. Using an MA to give weight-loss shots is a direct scope violation.

Telehealth Prescribing for Weight Loss in Tennessee

Telehealth is central to modern weight-loss programs, and Tennessee permits it — within limits that track the good-faith-exam doctrine.

Tennessee Allows It

Tennessee Code § 63-1-155 permits a provider to establish a valid provider-patient relationship through telehealth technologies, and a prior in-person visit is generally not required to initiate care. Because GLP-1 receptor agonists are not controlled substances, the stricter federal in-person requirements that attach to controlled drugs do not apply to semaglutide or tirzepatide. A Tennessee-licensed prescriber can therefore evaluate a weight-loss patient and prescribe after a telehealth encounter.

The Same Standard of Care Applies

Tennessee is explicit that telehealth care is held to the same standard of care as an in-person encounter. Telehealth changes the medium, not the requirement. A real-time, synchronous encounter — ideally audio-video — is expected for the initial good-faith exam. A static online questionnaire that a clinician rubber-stamps is not a good-faith exam, and questionnaire-only "visits" are exactly the pattern boards discipline. The exam standard is identical regardless of whether the patient ends up on an injectable or an oral GLP-1 option.

Tennessee Telehealth Checklist for GLP-1

• Tennessee-licensed prescriber — the provider must hold an active Tennessee license
• Patient located in Tennessee at the time of service (or the provider appropriately licensed where the patient is)
• Synchronous encounter for the initial good-faith exam — not an intake form alone
• Telemedicine noted in the chart — document that the encounter was conducted by telemedicine and the technology used
• Follow-up availability and a HIPAA-compliant platform with accessible records

Compounded Semaglutide and Tirzepatide: Sourcing Rules

Sourcing is where many Tennessee weight-loss programs carry hidden risk, because the legal ground shifted sharply when the FDA shortages ended.

The Federal Baseline: The Compounding Era Ended

The FDA removed tirzepatide from its shortage list in October 2024 and semaglutide in February 2025. Once a drug is off the shortage list, Section 503A pharmacies can no longer routinely compound copies of the FDA-approved product. The compounded-vial model that built thousands of weight-loss programs is no longer broadly legal. We break down the distinctions in the compounded GLP-1 503A vs 503B sourcing guide.

503A vs 503B

A 503A pharmacy compounds patient-specific prescriptions; a 503B outsourcing facility compounds larger batches under stricter FDA oversight. Neither can freely produce copies of an FDA-approved GLP-1 now that the shortages have resolved. Narrow exceptions remain — for example, a documented clinical need such as an allergy to an inactive ingredient in the branded product — but "cheaper" is not a clinical need, and volume compounding of standard semaglutide or tirzepatide no longer has a shortage justification.

Tennessee's Board of Pharmacy Overlay

A Tennessee prescriber who continues to rely on compounded GLP-1 without a documented, patient-specific clinical need faces exposure on two fronts: the Board of Medical Examiners (for prescribing outside the standard of care) and the Tennessee Board of Pharmacy (which regulates compounding and pharmacy licensure). Verify that any compounding partner is a properly licensed 503A pharmacy or 503B facility, and that any out-of-state mail-order partner holds current Tennessee licensure, before a single prescription goes out.

What Tennessee Med Spas Should Source

The defensible default in 2026 is the FDA-approved branded product: semaglutide (Wegovy for weight loss, Ozempic for diabetes) and tirzepatide (Zepbound for weight loss, Mounjaro for diabetes), plus liraglutide (Saxenda), dispensed by a properly licensed pharmacy on a valid prescription from a Tennessee-licensed prescriber. As branded supply and pricing have stabilized, the branded route is both the safer and increasingly the more practical choice.

Physician Supervision, Delegation, and Chart Review

Where mid-level prescribers do the day-to-day work, Tennessee sets concrete oversight duties for the collaborating or supervising physician — and these are inspected.

Chart Review and Site Visits

Tennessee's supervision framework for APRNs and PAs includes real, quantified duties: the supervising physician must review a defined share of charts (commonly cited as at least 20% of charts written by the supervisee) and, for remote practice sites, make periodic on-site visits (commonly at least once every 30 days). For a multi-location GLP-1 operation, this shapes how many sites and mid-levels a single physician can realistically cover — "covering" means genuine oversight, not a name on a form.

Written Protocols and the Delegation Chain

The collaborative practice agreement (for APRNs) or supervisory agreement (for PAs) must be a written, dated, signed protocol maintained at the practice site, and it should be updated on a regular cycle. For a GLP-1 program, the protocol should name weight-management prescribing explicitly, so the mid-level's authority to evaluate and prescribe semaglutide or tirzepatide is documented rather than assumed. The delegation chain then runs cleanly: registered physician → prescriber (physician, APRN, or PA) performing the good-faith exam → RN administering under order.

Supervision Must Be Real

Tennessee enforcement, like every state's, targets absentee supervision — a physician paid to be listed but who never reviews charts, never updates protocols, and is unreachable. Because the medical spa rule ties the whole facility to a named registered physician, a bad program can implicate that physician directly. Documented chart review, current signed agreements, and reachability for clinical questions are what turn a paper structure into a defensible one.

The Medical Director's Role in a GLP-1 Program

Because Tennessee's medical spa rule requires a registered physician, the medical director is not optional infrastructure — the program is legally built around them.

Statutory Duties

The registered supervising physician or medical director owns the clinical program: approving the GLP-1 SOP, the delegation and collaborative or supervisory agreements, the consent forms, and the chart-review schedule. Their name and certification appear in the practice's signage and advertising under the registration rule, which means their reputation is publicly attached to the program's conduct.

Genuine Oversight, Not a Signature

The medical director's involvement must be real. A physician who signs agreements but never reviews charts, never updates protocols, and cannot be reached is exactly the arrangement boards treat as a violation — and because the registration ties the facility to that physician, both the individual and the practice are exposed. Genuine oversight looks like documented chart review, current signed protocols, availability for clinical questions, and periodic site presence where required.

The Agreement

The medical director relationship should be governed by a written agreement that pays fair market value for actual services rendered — never a percentage of medical revenue, which raises fee-splitting concerns. Compensation should reflect the real time spent on oversight, chart review, protocol maintenance, and availability. A weight-loss program that runs at volume demands more of the medical director than a low-acuity service, and the agreement should reflect that.

Monitoring and Documentation a Tennessee Program Requires

Tennessee follows the general standard of care for GLP-1 monitoring rather than a drug-specific statute — which means a defensible program builds its own documented monitoring cadence and follows it.

Baseline Before Therapy

Document a baseline evaluation before the first dose: measured weight and BMI, blood pressure, relevant medical and medication history, the contraindication screen, and any labs indicated by the patient's comorbidities (for example, A1c or renal function where clinically appropriate). This baseline is what medical necessity and later progress are measured against.

Titration and Follow-Up

Expect a recall roughly four weeks after initiation and then every four to twelve weeks during dose escalation. At each visit, check tolerance, weight trend, blood pressure, and adverse effects — persistent GI symptoms, signs of pancreatitis, or gallbladder disease. A structured monitoring schedule keeps the program clinically sound and audit-ready; our GLP-1 monitoring schedule template lays out a visit-by-visit cadence you can adapt.

Documentation and the Chart-Review Loop

Because the supervising physician has a chart-review duty, monitoring is not just clinically wise — it has to be documented and reviewable. Chart the follow-up encounters, dose changes, adverse events, and the rationale for continuation, discontinuation, or a maintenance plan. An adverse-event log for GI events, suspected pancreatitis, and gallbladder events closes the loop and gives the medical director something concrete to review.

Building a Compliant Tennessee GLP-1 Program

Pulling the pieces together, here is the operational stack a Tennessee GLP-1 program should be able to produce on demand in 2026.

The Structural Layer

1. Medical spa registration — the facility registered with the Board of Medical Examiners under a licensed MD or DO who accepts responsibility for cosmetic medical services
2. Prescriber agreements — collaborative practice agreements (APRN) or supervisory agreements (PA), written, signed, dated, and naming weight-management prescribing
3. Medical director agreement — written, fair-market-value, no fee-splitting, reflecting real oversight time

The Clinical Layer

1. Written GLP-1 SOP signed by the medical director — eligibility, contraindications, titration, monitoring, discontinuation
2. Good-faith exam template performed only by a physician, APRN, or PA
3. Delegation orders authorizing RN administration, tied to a prior good-faith exam
4. Informed consent (including off-label and boxed-warning disclosures) and, where relevant, telehealth documentation
5. Contraindication screening checklist — MTC/MEN-2, pancreatitis, pregnancy, gastroparesis, renal/hepatic

The Operational Layer

1. Pharmacy documentation — properly licensed pharmacy partner on file; no undocumented compounded sourcing
2. Follow-up workflow — recall at 4 weeks, then every 4–12 weeks during titration, with scheduled monitoring
3. Supervision documentation — chart-review logs, current signed agreements, site-visit records where required
4. Adverse-event log — GI events, suspected pancreatitis, gallbladder events

Every one of those documents can be built from a proven template rather than drafted from scratch. Our ready-to-use med spa SOP library and the state-specific Tennessee med spa compliance checklist give you the structural, clinical, and operational pieces in a format you can adapt to your practice. For the full picture of every Tennessee-specific guide in one place, start at the Tennessee compliance hub.

The Bottom Line for Tennessee Operators

Tennessee will not forgive a GLP-1 program that ignores the medical spa registration rule or a workflow that delegates the good-faith exam to someone who cannot legally perform it. But the rules are knowable, and a program built on them is both defensible and scalable. The operators who win in Tennessee treat the legal structure as part of the product, not an afterthought:

1. Register the med spa under a licensed physician who genuinely accepts responsibility for the medical services
2. Keep prescribing with a physician, an APRN under a collaborative practice agreement, or a PA under a supervisory agreement — never an RN, MA, or owner
3. Perform the good-faith exam before any injection, and never delegate it to a nurse
4. Use RN administration only under valid physician delegation tied to that exam
5. Treat telehealth as a real encounter held to the in-person standard of care
6. Source FDA-approved branded product through properly licensed pharmacies, and document any compounding exception
7. Monitor, document, and review — so the chart-review loop can actually close

Do those things and you have a Tennessee GLP-1 program that can survive a Board of Medical Examiners, Board of Nursing, or Board of Pharmacy look.

Disclaimer: This article is for educational purposes only and does not constitute legal or medical advice. Tennessee's medical spa registration, scope-of-practice, telehealth, and pharmacy rules are complex and change frequently. Verify current FDA shortage status and consult a Tennessee healthcare attorney and your medical director before establishing or modifying a weight-loss program.